It looks fairly good that Dominion Capital may want to hold there 7% stake and possibly be a long term Financing arm (as least for now). I think this is very significant news as it can lift some uncertainty regarding those who are holding back with investing here.
As Jason Napadano (Zacks Analyst) has stated:
Conclusion:
Based on the current stock price, Amarantus is trading with a market capitalization of only $16 million. We acknowledge the company's tenuous financial position, but believe that LymPro alone is worth $50 million. If Becton, Dickinson likes what they see in the validation studies we expect the company to then seek to in-license the candidate from Amarantus and push forward toward CLIA approval in 2014. Amarantus has been talking more and more about concussion awareness and the opportunity for MANF in this indication. We note the #C4CT Concussion Awareness Summit takes place in Minneapolis on Friday, June 21 and are looking forward to hearing what comes out of the conference in this regard. Finally, a new opportunity in LID looks like it may be emerging, and with no approved therapies this could be significant for shareholders.
Amarantus has built (and is continuing to build) a portfolio of assets that lead us to conclude the current valuation of only $16 million is far too low. A catalyst for driving valuation higher might just be raising capital to drive these opportunities forward.
